Plexium develops a targeted protein degradation platform utilizing proprietary ultra-high throughput cell-based screening technology to create monovalent targeted protein degrader therapeutics. The company focuses on discovering new therapies for cancer and neurological conditions by rationally designing protein degraders that selectively eliminate disease-causing proteins.
Funding
$165M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BVTCFounders
Product
Problem
Current targeted protein degradation (TPD) approaches often struggle with inefficient degradation and off-target effects due to reliance on bivalent degraders and limited screening methodologies. This results in challenges in developing effective and selective therapeutics for diseases like cancer and neurological disorders.
Solution
Plexium is developing monovalent targeted protein degrader therapeutics using a proprietary ultra-high throughput cell-based screening (uHTS) technology. This platform enables the rational design and discovery of direct degraders and molecular glues that selectively eliminate disease-causing proteins. By focusing on monovalent degraders, Plexium aims to achieve greater precision and reduce off-target effects compared to traditional bivalent approaches. The company's comprehensive TPD platform allows for pushing the boundaries of TPD, creating limitless possibilities.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for cancer, neurological conditions, and other diseases with unmet medical needs.
Features
- Proprietary ultra-high throughput cell-based screening (uHTS) technology for identifying novel protein degraders
- Rational design of Monovalent Direct Degraders and Molecular Glues
- Focus on monovalent degraders for improved selectivity and reduced off-target effects
- Development of therapeutics for cancer and neurological conditions
- Partnerships with pharmaceutical companies to discover new monovalent degraders